Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

SML2868

Sigma-Aldrich

Aclidinium bromide

≥98% (HPLC)

Synonym(s):

(3R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide, (3R)-3-[(2-Hydroxy-2,2-di-2-thienylacetyl)oxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C26H30BrNO4S2
CAS Number:
320345-99-1
Molecular Weight:
564.55
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -24 to -30°, c = 0.1 in methanol

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

InChI

1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1

InChI key

XLAKJQPTOJHYDR-QTQXQZBYSA-M

Biochem/physiol Actions

Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) bronchodilator. It is a muscarinic M3, M2 antagonist with a long residence time at M3 receptors and a shorter residence time at M2 receptors. Aclidinium bromide was approved for the treatment of chronic obstructive pulmonary disease (COPD) in July 2012.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Amadeu Gavaldà et al.
The Journal of pharmacology and experimental therapeutics, 331(2), 740-751 (2009-08-28)
Aclidinium bromide is a novel potent, long-acting inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease. Aclidinium showed subnanomolar affinity for the five human muscarinic receptors (M(1)-M(5)). [(3)H]Aclidinium dissociated slightly faster from M(2) and M(3) receptors
Z-Z Li et al.
European review for medical and pharmacological sciences, 23(1), 105-112 (2019-01-19)
Osteosarcoma is recognized as the most common primary malignant bone tumor, the 5-year disease-free survival rate in patients with metastatic or recurrent disease is below than 30%. Drug resistance and toxic side effects limit the therapeutic efficacy of osteosarcoma. Therefore

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service